These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 7826031)
1. Role of EBV and Ig/myc translocation in Burkitt lymphoma. Klein G Antibiot Chemother (1971); 1994; 46():110-6. PubMed ID: 7826031 [No Abstract] [Full Text] [Related]
2. Analysis of viral gene expression and genome persistence in CD23-positive and -negative subpopulations of Epstein-Barr-virus-infected BL2 cells. Doyle MG; Crawford DH Intervirology; 1994; 37(5):236-44. PubMed ID: 7698878 [TBL] [Abstract][Full Text] [Related]
3. EBV and Burkitt's lymphoma. Rossi G; Bonetti F N Engl J Med; 2004 Jun; 350(25):2621; author reply 2621. PubMed ID: 15201422 [No Abstract] [Full Text] [Related]
4. A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. Chen F; Zou JZ; di Renzo L; Winberg G; Hu LF; Klein E; Klein G; Ernberg I J Virol; 1995 Jun; 69(6):3752-8. PubMed ID: 7745723 [TBL] [Abstract][Full Text] [Related]
5. Integration of a short Epstein-Barr virus DNA fragment in a B95-8 virus converted Burkitt lymphoma line expressing Epstein-Barr nuclear antigens EBNA2 and EBNA5. Trivedi P; Cuomo L; de Campos-Lima PO; Imreh MP; Kvarnung K; Klein G; Masucci MG J Gen Virol; 1993 Jul; 74 ( Pt 7)():1393-8. PubMed ID: 8393080 [TBL] [Abstract][Full Text] [Related]
6. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641 [TBL] [Abstract][Full Text] [Related]
7. Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells. Sugiura M; Imai S; Tokunaga M; Koizumi S; Uchizawa M; Okamoto K; Osato T Br J Cancer; 1996 Aug; 74(4):625-31. PubMed ID: 8761381 [TBL] [Abstract][Full Text] [Related]
8. Pharmacologic activation of expression of immunodominant viral antigens: a new strategy for the treatment of Epstein-Barr-virus-associated malignancies. Robertson KD; Barletta J; Samid D; Ambinder RF Curr Top Microbiol Immunol; 1995; 194():145-54. PubMed ID: 7534666 [No Abstract] [Full Text] [Related]
9. Down-regulation of integrated Epstein-Barr virus nuclear antigen 1 and 2 genes in a Burkitt lymphoma cell line after somatic cell fusion with autologous EBV-immortalized lymphoblastoid cells. Wolf J; Pawlita M; Klevenz B; Frech B; Freese UK; Müller-Lantzsch N; Diehl V; zur Hausen H Int J Cancer; 1993 Feb; 53(4):621-7. PubMed ID: 8382194 [TBL] [Abstract][Full Text] [Related]
10. EBNA2 and c-myc in B cell immortalization by Epstein-Barr virus and in the pathogenesis of Burkitt's lymphoma. Zimber-Strobl U; Strobl L; Höfelmayr H; Kempkes B; Staege MS; Laux G; Christoph B; Polack A; Bornkamm GW Curr Top Microbiol Immunol; 1999; 246():315-20; discussion 321. PubMed ID: 10396071 [No Abstract] [Full Text] [Related]
11. Induction of Epstein-Barr virus (EBV) reactivation in Raji cells by doxorubicin and cisplatin. Hsu CH; Hergenhahn M; Chuang SE; Yeh PY; Wu TC; Gao M; Cheng AL Anticancer Res; 2002; 22(6C):4065-71. PubMed ID: 12553034 [TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis. Bieging KT; Amick AC; Longnecker R Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17945-50. PubMed ID: 19815507 [TBL] [Abstract][Full Text] [Related]
14. Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints. Gruhne B; Sompallae R; Masucci MG Oncogene; 2009 Nov; 28(45):3997-4008. PubMed ID: 19718051 [TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. Kennedy G; Komano J; Sugden B Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14269-74. PubMed ID: 14603034 [TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus in lymphoproliferative processes: an update for the diagnostic pathologist. Ng SB; Khoury JD Adv Anat Pathol; 2009 Jan; 16(1):40-55. PubMed ID: 19098466 [TBL] [Abstract][Full Text] [Related]
17. Expression of Epstein-Barr virus-encoded latent membrane protein 1 in nonendemic Burkitt's lymphomas. Carbone A; Gloghini A; Zagonel V; Tirelli U Blood; 1996 Feb; 87(3):1202-4. PubMed ID: 8562951 [No Abstract] [Full Text] [Related]
18. Epstein-Barr virus recombinants from BC-1 and BC-2 can immortalize human primary B lymphocytes with different levels of efficiency and in the absence of coinfection by Kaposi's sarcoma-associated herpesvirus. Aguirre AJ; Robertson ES J Virol; 2000 Jan; 74(2):735-43. PubMed ID: 10623735 [TBL] [Abstract][Full Text] [Related]
19. Amplification and deregulation of MYC following Epstein-Barr virus infection of a human B-cell line. Lacy J; Summers WP; Watson M; Glazer PM; Summers WC Proc Natl Acad Sci U S A; 1987 Aug; 84(16):5838-42. PubMed ID: 3039510 [TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus and the immune system. Hide and seek. Cohen JI JAMA; 1997 Aug; 278(6):510-3. PubMed ID: 9256227 [No Abstract] [Full Text] [Related] [Next] [New Search]